Genotoxicity and Cytotoxicity of novel 10B carrier ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid
Journal Title: Medical Science and Discovery - Year 2014, Vol 1, Issue 4
Abstract
Objective: Although surgery and chemotherapy have been greatly successful in the treatment of many types of tumors, these treatment modalities have some limitations. In particular, the side effects of conventional radiotherapy warrant the development of new therapy methods, such as Boron Neutron Capture Therapy (BNCT). In the present study, the cytotoxic and genotoxic properties of novel synthesized boron carrier, ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid (10BDG), and the apoptotic pathways triggered by 10BDG were examined. Material and Methods: As it defined previously, 10BDG was complexed through a low-high pH reaction and was tested using a Fournier Transform InfraRed-Attenuated Total Reflectance (FT-IR/ATR) spectrophotometer. The cytotoxicity of 10BDG was tested through the MTT assay. The detection of caspases 3, 8, and 9 was performed to determine the activated apoptotic pathways by 10BDG. The Poly (ADP-Ribose) Polymerase (PARP) cleavage and DNA damage induced by this compound were tested through western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, respectively. Results: The average LogIC50 and LogLD50 levels of 10BDG over NCI-H209 cell line were to be found 72.1±10 ug/ml and 171.8±25 mg/kg, respectively. Caspase-9 activation, caspase-3 activation, PARP cleavage, and caspase-3-dependent DNA fragmentation were observed. The genotoxicity analysis was performed using the plasmid fragmentation assay, which revealed the absence of fragmentation. Conclusion: Bio-distrubition analysis showed that boron content was elevated to 12.63 from 4.44 ppm in the tumor tissue by the 10BDG injections. In epitome, 10BDG exhibit slight cytotoxic but no genotoxic properties. Based on the antiproliferative properties of 10BDG, in addition to acting as an adjuvant in cancer radiotherapy and chemotherapy, this compound appears to be an alternative boron carrier for BNCT
Authors and Affiliations
Zafer Akan, Hulya Ozdemir, Gokhan Oto, Sabahattin Deniz, Omer Kacar, Ali Sadi Basak, Tahir Cakir, Hatice Uslu Sinav, Goksel Demir
Keywords
Related Articles
- EP ID EP520346
- DOI -
- Views 32
- Downloads 0
Examination of echocardiographic parameters for the early diagnosis of cardiac dysfunction in beta thalassemia major patients
Objective: This study aimed to determine the utility of tissue Doppler, pulse-wave Doppler, and conventional echocardiography for the detection of cardiac dysfunction in the early period in beta thalassemia patients....
Endovascular therapy of isolated internal iliac artery aneurysm
Isolated internal iliac artery (IIA) aneurysms are relatively uncommon. Isolated IIA aneurysms traditionally have been treated by surgical reconstruction. We report our experience with endovascular treatment of isolated...
Secondary primary malignancy presence and related factors in chronic lymphocytic leukemia
Objective: The secondary primary malignancy frequencies have seen increased in chronic lymphocytic leukemia (CLL) regardless of therapy. The aim of this study was to investigate the frequency of secondary prim...
Ultrasound-guided cannulation in placement of Hemodialysis Access Catheters in Predialysis Patients
Aim: Ultrasound (USG)-guided hemodialysis catheter placement is known to be superior to and more reliable than catheter insertion guided by anatomical landmarks. USG is used for vascular mapping (VM) before catheter plac...
Familial Recurrent Hydatidiform Moles: A rare case report
Recurrent hydatidiform moles (RHM) are described as the being of at least two molar pregnancies in the same patient. It is very rare. NLPR7 mutations are found high rate in patients with RHM. KHDC3L is the second respons...